Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 - 2026

Report Summary

预计2019年全球痛风治疗性市场规模预计将估值为2,442.8百万美元，预计预测期内的复合年增长率为14.8％。痛风是一种严重的关节炎形式，可以导致关节中疼痛的突然袭击。它的特征在于关节的严重疼痛，压痛和发红。它最常在大脚趾的球中发展。在脚踝，脚，脚跟，手腕，膝盖，肘部和手中的关节也可能受到影响。痛风市场上有几种治疗替代品。NSAID的或皮质类固醇可用于这种情况下引起的疼痛和炎症。此外，患有每年多重急性痛风攻击的人或在考试中的人们的人们主要提出了尿酸降低治疗。为了防止这种情况，鼓励所有患者改变他们的生活方式，并在每日习惯中带来一些变化，包括令人鼓舞的体重减轻，在适当的情况下，限制酒精摄入量和富含嘌呤的食物。

由于改变的生活方式模式和不断增长的老年人口，痛风治疗性市场主要推动这种情况的普遍性。在全球范围内，人们的预期寿命正在增加，这导致了老年人口崛起。这种趋势导致这种情况的发病率较高，对其治疗剂的人均需求，从而积极影响对这些治疗剂的需求。此外，越来越多的研发活动，重点是痛风治疗剂的创新和发展以及与痛风治疗相关的增长意识，进一步刺激了行业生长。此外，在生物制剂领域的创新以及根据其产生强大的抗炎行为的能力，还增加了这些产品的创新，也有望在预测期间推动该市场的增长。此外，工艺中有大量的临床试验，由于预计未来几年的许多新产品将推出。这也有望推动在预测期间的行业增长。然而，普遍部门竞争增加的因素，大片产品的专利到期，新发型药物的高成本可能会阻碍预测期间该行业的增长。

Know more about this report:请求样本页面

直到最近，患有相关代谢综合征患者痛风的诊断和治疗难度主要是由于有限的治疗方案。然而，随着时间的推移，在该领域中取得了重大进展，并引入了白细胞介素-1拮抗剂，Febuxostat和Pegloticase等新处理。目前，生物疗法是研究人员的主要关注点，其针对在发病机制中发挥关键作用的免疫系统的特异性要素。在市场上推出了几种新生物学，如Canakinumab，Krystexxa和Rilonacept。因为，在理解和管理痛风状态的过程中存在快速发展，正在引入几个疗法，因此正在创造在这个市场中的增长机会。

Various products such as non-steroidal anti-inflammatory drugs (nsaids), corticosteroids, colchicine, and urate lowering agents are used as treatment option for the patients suffering with gout. Companies operating in this industrial segment are continuously investing in research and development to improve the product efficacies are offer more appropriate and effective products. Numerous studies are being funded by government and private organizations across the globe. In October 2018, University of Otago was funded by the Royal Society Te Aparangi for research into the genetic causes of gout and related diseases in New Zealand. Furthermore, companies such as AstraZeneca, Horizon Pharma, Takeda Pharmaceutical, GlaxoSmithKline, Novartis, Merck & Co., and many others are launching and distributing new products in the market. For instance, in February 2016 AstraZeneca received marketing authorisation for Zurampic (lesinurad) from the European Commission (EC). Furthermore, in September 2019, Simcere Pharmaceutical Group entered into a collaboration and exclusive license agreement with JW Pharmaceutical, for anti-gout drug candidate URC-102 in China. Such activities are helping the companies enhance their presence and thus, drive the growth across the globe.

Gout Therapeutics Market Report Scope

该市场主要基于毒品类，疾病状况和地理区域进行分段。

By Drug Class	By Disease Condition	By Region
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Corticosteroids Colchicine 调整降低剂	急性 Chronic	North America (U.S., Canada) Europe (Germany, UK, France, Italy, Spain, Belgium, Rest of Europe) Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of Asia-Pacific) 拉丁美洲(拉丁美洲的巴西、墨西哥、其他) Middle East and Africa (South Africa, Saudi Arabia, Rest of MEA)

Know more about this report:请求样本页面

Drug Class Outlook

基于药物类,全球痛风治疗industry is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, and urate lowering agents. In 2019, NSAIDs accounted for the largest share in the industry. NSAIDs are the first line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. Rising number of gout patients, low cost of drugs, and application in combination therapy is likely to drive the market Indomethacin and naproxen are major choice for the acute attack of the gout. Urate lowering agents segment is expected to observe the highest growth during the forecast period. This is attributed to recently introduction of novel drugs, investment by several industry players for the development of urate lowering agents, and expected launch of anti-gout drugs during the forecast period. The growth of colchicine segment is also significant based on its efficacy and growing product development activities.

• In February 2019, ROMEG therapeutics received FDA approval of GLOPERBA (colchicine) for prophylaxis of adult gout flares.

Disease Condition Outlook

On the basis of disease condition, the industry is segmented into acute and chronic gout. In 2019, chronic segment accounted for the highest share of the market. This is attributed to introduction or commercialization of various drugs for chronic conditions and high cost of medicine. Urate lowering agents are utilized in chronic conditions. Whereas, colchicine, NSAIDs, and corticosteroids are preferred in acute.

The acute segment consists of colchicine, NSAIDs, and corticosteroids therapy. The segment accounted lesser share as compared to chronic therapeutics. This is attributed to low cost drugs, low adherence to the treatment, and drugs ability to relieve pain for shorter period. More penetration of therapeutics for acute conditions due to their early entry into market and low cost were the major driving factor for acute gout therapeutics segment.

Regional Outlook

North America dominated the industry due to due to the presence of major market players, affordability for high cost biologics and urate lowering agents, early introduction of drugs in the US, and presence of large patient base. Gout is common in most countries in North America affecting around 8.3 million people in the United States, with prevalence in the 1–4% range. The prevalence of gout is higher in African Americans as compared to Caucasians, with increasing prevalence overall across all demographics. The U.S. accounted for highest share in the North American region for this industry. Government initiatives to provide better healthcare facilities to all their residents, favorable reimbursement, presence of major market players, and high adoption of the high cost therapeutics are the key factors for the dominance of the market.

However, Asia Pacific is expected to observe the fastest growth during the forecast period due to increasing investment of market players in the region, rising awareness and healthcare spending, and expected entry of drugs in the region. Furthermore, rising patient pool, increasing investment by major players in the region, and rising adoption of gout therapy are also fueling the growth of this regional segment. Moreover, increasing prevalence of smoking & alcohol consumption and stressed lifestyle are likely to boost the incidence of gout during the forecast period.

Competitive Landscape

Companies are expanding their presence across various geographies and entering new markets in developing regions to expand their customer base and strengthen presence in the market. The companies are also introducing new innovative products in the market to cater to the growing consumer demands. The key leading players in the market include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.